bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company developing noninvasive healthcare solutions for the early detection and monitoring of lung disease, today announced that it is advancing the potential application of its CyPath® Lung test for surveillance of lung cancer patients who have completed curative-intent treatment.

Lung cancer recurrence remains a significant clinical challenge. According to the American Cancer Society, there were more than 680,000 Americans living with a prior lung cancer diagnosis as of January 1, 2025.1 The National Cancer Institute estimates that another 230,000 patients will be diagnosed with lung cancer in 2026.